SECTORS TODAY
Tech XLK -4.89%
Financials XLF -0.76%
Healthcare XLV +0.45%
Energy XLE +1.91%
Industrials XLI -1.60%
Cons. Disc. XLY -0.71%
Cons. Staples XLP +1.41%
Utilities XLU +0.67%
Materials XLB +0.40%
Real Estate XLRE +0.26%
Comm. Svcs XLC -1.29%

Earnings release · IQV

IQVIA Reports Third-Quarter 2026 Results

Iqvia Holdings Inc. · Filed · SEC Form 8-K, Item 2.02

Iqvia Holdings Inc. company page Original on SEC.gov ↗

Revenue $4,428 million +8% vs a year ago
EPS $2.10 not detected
Guidance raisedoutlook statement
Automated extract. The items below were picked out of the company's press release by software and may be wrong or incomplete. Please read the original before relying on any figure. Not investment advice.

Why it matters

Revenue increased 8% year on year to $4,428 million, and EPS was $2.10. Management raised its outlook, and guidance changes often matter more to the market than the quarter just reported because they reflect expectations for the periods ahead.

Written automatically by Stocknote's note engine from the figures on this page and the company's previous release. Every number in this note is checked against those figures. Not investment advice.

What the company states

Revenue

$4,428 million +8% vs a year ago

…Revenue $4,428 million, up 8.0% year-over-year, up 8.6% at constant currency…
EPS

$2.10

…GAAP Diluted Earnings per Share $2.10, Adjusted Diluted Earnings per Share $3.34, up 11.3% year-over-year…
Guidance

Guidance raised

…Raising full-year 2026 guidance for Revenue, Adjusted EBITDA and Adjusted Diluted Earnings per Share | The company is raising its full-year 2026 guidance for revenue to be between $17,350 million and $17,500 million, for Adjusted EBITDA to be between $4,025 million and $4,055 mil…

Read the original press release on SEC.gov ↗ Filing index ↗

Disclaimer: This page is generated automatically from public SEC filings for information only. Stocknote does not edit the company's release and does not guarantee the accuracy of the extracted items. Read the full disclaimer here.

Get new research in your inbox

Forensic equity research on US stocks. No spam, unsubscribe anytime.